NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02940925,TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma,https://clinicaltrials.gov/study/NCT02940925,,COMPLETED,"The purpose of this study is to compare the survival and toxicity of TPC (TAXOL, DDP AND CAPECITABINE ) VS PF (cisplatin and 5-Fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for stage IVa-b nasopharyngeal carcinoma patients in endemic area.",NO,Nasopharyngeal Carcinoma,"OTHER: Drug: Taxol,cisplatin and capecitabine|OTHER: Drug: Cisplatin and 5-Fluorouracil","Failure-free survival calculated from randomisation to locoregional failure, distant failure, or death from any cause, up to 5 years","Overall survival calculated from randomisation to death from any cause, up to 5 years|Progression free survival calculated from randomisation to disease progression or death from any cause, up to 5 years|Local-regionally relapse free survival calculated from randomisation to locoregional failure, up to 5 years|Distant metastasis free survival calculated from randomisation to distant failure, up to 5 years|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, up to 5 years",,Sun Yat-sen University,,ALL,ADULT,PHASE3,241,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,20160049,2016-10-20,2021-08-28,2021-08-31,2016-10-21,,2023-04-12,"SunYat-senU, Guangzhou, Guangdong, 510060, China",
